UCB adds Nayzilam to epilepsy armory in USA

Belgian biopharma UCB (Euronext: UCB) started the week by announcing that the US Food and Drug Administration (FDA) has approved Nayzilam (midazolam) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy.

Nayzilam becomes the first FDA-approved nasal option for treating seizure clusters, which are estimated to affect 150,000 Americans with uncontrolled epilepsy.

Prior to Nayzilam, there had not been a new medication approved to treat seizure clusters in more than 20 years in the USA.
Rescue treatment of seizure clusters is critical because, when left untreated, seizure clusters can increase the risk of physical injury, neurological damage, prolonged seizures, and status epilepticus.